fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
Company profile
Ticker
FGEN
Exchange
Website
CEO
Enrique Conterno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Beijing Falikang Pharmaceutical Co., Ltd. • FibroGen (China) Medical Technology Development Co., Ltd. • FibroGen China Anemia Holdings, Ltd. • FibroGen Europe • FibroGen International (Cayman) Limited • FibroGen International • Skin Sciences, Inc. ...
FGEN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
FibroGen Reports Third Quarter 2023 Financial Results
6 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Oct 23
8-K
Departure of Directors or Certain Officers
5 Oct 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
Transcripts
FGEN
Earnings call transcript
2023 Q4
26 Feb 24
FGEN
Earnings call transcript
2023 Q3
6 Nov 23
FGEN
Earnings call transcript
2023 Q2
7 Aug 23
FGEN
Earnings call transcript
2023 Q1
8 May 23
FGEN
Earnings call transcript
2022 Q4
27 Feb 23
FGEN
Earnings call transcript
2022 Q3
8 Nov 22
FGEN
Earnings call transcript
2022 Q2
9 Aug 22
FGEN
Earnings call transcript
2022 Q1
10 May 22
FGEN
Earnings call transcript
2021 Q4
1 Mar 22
FGEN
Earnings call transcript
2021 Q3
10 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 120.91 mm | 120.91 mm | 120.91 mm | 120.91 mm | 120.91 mm | 120.91 mm |
Cash burn (monthly) | 10.56 mm | 2.92 mm | 21.16 mm | 24.48 mm | 28.18 mm | 29.10 mm |
Cash used (since last report) | 72.44 mm | 20.04 mm | 145.21 mm | 167.99 mm | 193.37 mm | 199.70 mm |
Cash remaining | 48.47 mm | 100.87 mm | -24.30 mm | -47.08 mm | -72.46 mm | -78.78 mm |
Runway (months of cash) | 4.6 | 34.5 | -1.1 | -1.9 | -2.6 | -2.7 |
Institutional ownership, Q3 2023
72.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 111 |
Opened positions | 14 |
Closed positions | 66 |
Increased positions | 32 |
Reduced positions | 44 |
13F shares | Current |
---|---|
Total value | 57.17 bn |
Total shares | 71.31 mm |
Total puts | 62.80 k |
Total calls | 1.94 mm |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Primecap Management | 14.72 mm | $12.71 bn |
Vanguard | 9.06 mm | $7.82 bn |
BLK Blackrock | 8.04 mm | $6.93 bn |
Armistice Capital | 7.89 mm | $6.81 bn |
First Trust Portfolios | 2.98 mm | $0.00 |
Jacobs Levy Equity Management | 2.56 mm | $2.21 bn |
Millennium Management | 2.27 mm | $1.96 bn |
Assenagon Asset Management | 2.23 mm | $1.92 bn |
Geode Capital Management | 1.88 mm | $1.63 bn |
Two Sigma Investments | 1.86 mm | $1.61 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Mar 24 | Thane Wettig | Common Stock | Payment of exercise | Dispose F | No | No | 2.58 | 782 | 2.02 k | 469,396 |
7 Mar 24 | Thane Wettig | Common Stock | Buy | Acquire P | No | No | 1.9094 | 50,000 | 95.47 k | 470,178 |
6 Mar 24 | Thane Wettig | Common Stock | Payment of exercise | Dispose F | No | No | 1.87 | 326 | 609.62 | 420,178 |
6 Mar 24 | Thane Wettig | Common Stock | Grant | Acquire A | No | No | 0 | 781 | 0.00 | 420,504 |
6 Mar 24 | Thane Wettig | Common Stock | Payment of exercise | Dispose F | No | No | 1.87 | 4,209 | 7.87 k | 419,723 |
6 Mar 24 | Chung Christine | Common Stock | Payment of exercise | Dispose F | No | No | 1.87 | 422 | 789.14 | 341,028 |
6 Mar 24 | Chung Christine | Common Stock | Grant | Acquire A | No | No | 0 | 781 | 0.00 | 341,450 |
6 Mar 24 | Chung Christine | Common Stock | Payment of exercise | Dispose F | No | No | 1.87 | 23,168 | 43.32 k | 340,669 |
News
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
3 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
3 Apr 24
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
3 Apr 24
FibroGen Reports Data From Fortis Therapeutics-Sponsored Phase 1 Study Of FG-3246
2 Apr 24
Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
12 Mar 24
Press releases
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
24 Apr 24
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
2 Apr 24
Thinking about buying stock in Infobird, PubMatic, Hims & Hers Health, FibroGen, or Alpha Metallurgical Resources?
27 Feb 24